Brian Lichty

PhD, Associate Professor, Pathology and Molecular Medicine, McMaster

Full Biography

Cancers of Interest

Breast
Cervical
Gynecological
Lung
Prostate
Skin

Projects at BioCanRx

Development of a Virally Programmed Exosome-based Cancer Vaccine Platform

COMBINING ONCOLYTIC VACCINE THERAPY WITH ADOPTIVE CELL THERAPY TO TARGET CANCERS EXPRESSING MAGE-A3

A Phase 1/1b, Multicenter, Open-label Trial of Oncolytic MG1 Expressing Mutant Human Papilloma Virus (HPV) E6 and E7 (MG1-E6E7), with Adenovirus Vaccine Expressing Mutant HPV E6 and E7 (Ad-E6E7) and Atezolizumab in Patients with HPV Associated Cancers

ADVANCED PRECLINICAL DEVELOPMENT OF THE ONCOLYTIC VACCINE PLATFORM TO PREPARE REQUIREMENTS FOR A CLINICAL TRIAL OF PATIENTS WITH HPV-ASSOCIATED CANCERS

Recent Articles

Ontario start-up makes major deal to develop cancer-fighting viruses

Removing obstacles to innovation: BioCanRx core facilities provide essential manufacturing, immune analysis services

BioCanRx and partners announce $6.5M in funding for three new projects including a clinical trial

Cancer patients treated in world-first clinical trial of Canadian viral therapy